Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.
Nakazawa M, Fang M, Vong T, Zorzi J, Griffith P, Anders RA, Oshima K, Kim AK, Laurin J, Lafaro KJ, Shubert CR, Burns WR, He J, Burkhart RA, Philosophe B, Meyer J, Liddell RP, Georgiades C, Hong K, Ho WJ, Baretti M, Strauss AT, Yarchoan M.
Nakazawa M, et al. Among authors: kim ak.
Cancer Res Commun. 2024 Aug 1;4(8):2123-2132. doi: 10.1158/2767-9764.CRC-24-0151.
Cancer Res Commun. 2024.
PMID: 39142659
Free PMC article.